Can cause hypersensitivity reactions. If hypersensitivity reactions or signs of intolerance occur during administration, immediately stop treatment. Must not be administered by SC or IM route. Reports of symptomatic hypophosphataemia leading to osteomalacia & fractures requiring clinical intervention including surgery. Monitor serum phosphate in patients who receive multiple administrations at higher doses or long-term treatment & those w/ existing risk factors for hypophosphataemia. Caution in case of acute or chronic infection, asthma, eczema or atopic allergies. Recommended to stop Ferinject treatment in patients w/ ongoing bacteraemia. Avoid paravenous leakage. In case of paravenous leakage, immediately stop administration. Patients on a Na-controlled diet. Patients w/ liver dysfunction. Avoid parenteral Fe administration in patients w/ hepatic dysfunction where Fe overload is a precipitating factor, in particular porphyria cutanea tarda. Should not be used during pregnancy unless clearly necessary. Treatment w/ Ferinject should be confined to the 2nd & 3rd trimester if the benefit is judged to outweigh the potential risk for both mother & foetus. Not recommended in childn <14 yr.
Sign Out
